Related Experiment Video
Updated: Feb 15, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
A synthetic combinatorial approach to disabling deviant Hedgehog signaling
C-W Fan1, N Yarravarapu1, H Shi2
1Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Abstract:
Mutations in components of the Hedgehog (HH) signal transduction pathway are found in the majority of basal cell carcinoma (BCC) and medulloblastoma incidents. Cancerous cells with intrinsic or acquired resistance to antagonists targeting the seven transmembrane effector Smoothened (SMO) frequently invoke alternative mechanisms for maintaining deviant activity of the GLI DNA binding proteins. Here we introduce a chemical agent that simultaneously achieves inhibition of SMO and GLI activity by direct targeting of the SMO heptahelical domain and the GLI-modifying enzymes belonging to the histone deacetylase (HDAC) family. We demonstrate a small molecule SMO-HDAC antagonist (IHR-SAHA) retains inhibitory activity for GLI transcription induced by SMO-dependent and -independent mechanisms frequently associated with cancer biogenesis. Synthetic combinatorial therapeutic agents such as IHR-SAHA that a priori disable cancer drivers and anticipated mechanisms of drug resistance could extend the duration of disease remission, and provide an alternative clinical development path for realizing combinatorial therapy modalities.
Insights
A novel dual-action drug (IHR-SAHA) inhibits both Smoothened (SMO) and histone deacetylase (HDAC) pathways. This approach targets cancer drivers and resistance mechanisms in basal cell carcinoma and medulloblastoma.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Mutations in the Hedgehog (HH) signaling pathway are prevalent in basal cell carcinoma (BCC) and medulloblastoma.
- Cancer cells develop resistance to Smoothened (SMO) antagonists by activating alternative GLI transcription factor pathways.
Purpose of the Study:
- To develop a novel therapeutic agent targeting both SMO and GLI activity.
- To investigate a dual SMO-HDAC antagonist for overcoming drug resistance in cancers driven by HH pathway mutations.
Main Methods:
- Design and synthesis of a small molecule SMO-HDAC antagonist (IHR-SAHA).
- Evaluation of IHR-SAHA's inhibitory activity against SMO-dependent and SMO-independent GLI transcription.
- Assessment of IHR-SAHA's potential in cancer biogenesis and drug resistance models.
Main Results:
- IHR-SAHA effectively inhibits GLI transcription through simultaneous targeting of the SMO heptahelical domain and histone deacetylase (HDAC) enzymes.
- The compound demonstrates efficacy against SMO-dependent and SMO-independent mechanisms of GLI activation.
- IHR-SAHA shows potential as a combinatorial therapeutic agent against cancer drivers and resistance pathways.
Conclusions:
- Dual inhibition of SMO and HDAC pathways represents a promising strategy for treating HH-driven cancers.
- Synthetic combinatorial agents like IHR-SAHA can disable cancer drivers and anticipated resistance mechanisms.
- This approach may prolong disease remission and offers a new clinical development path for combination therapies.
Related Concept Videos
Hedgehog Signaling Pathway
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Intellectual Disability
Learning Disabilities
Dyslexia
Dyslexia is a...
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Synthetic Disvision of Polynomials

